New hope to halt river blindness: testing a Twice-Yearly treatment
NCT ID NCT03876262
Summary
This study is testing whether a drug called moxidectin, given once or twice a year, is safe and works better than the current standard drug, ivermectin, to control the parasite that causes river blindness. The trial involves over 300 people in the Democratic Republic of Congo who have the infection. Researchers are measuring if the treatments can keep the parasite at undetectable levels in the skin and eyes for a full year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCHOCERCIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre de Recherche pour les Maladies Tropicales Negligees
Rethy, Ituri, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.